Latest Articles

Publication Date
All News Scientific
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive

Published: June 24, 2024, 7 a.m.
Read Full Article
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress

FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress

Published: June 24, 2024, 7 a.m.
Read Full Article
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay

FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay

Published: June 21, 2024, 7 a.m.
Read Full Article
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers

Published: June 20, 2024, 7 a.m.
Read Full Article
FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer - Oncology News Central

FDA Approves Durvalumab Combination for Advanced or Recurrent Endometrial Cancer Oncology News Central

Published: June 17, 2024, 7 a.m.
Read Full Article
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive

FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive

Published: June 17, 2024, 7 a.m.
Read Full Article
ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone - Medpage Today

ASCO Reading Room | Sound Evidence to Treat Smaller, Recurrent Endometrial Cancers With Radiotherapy Alone Medpage Today

Published: June 5, 2024, 7 a.m.
Read Full Article
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates - PR Newswire

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire

Published: June 1, 2024, 7 a.m.
Read Full Article
Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer - OncLive

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer OncLive

Published: April 24, 2024, 7 a.m.
Read Full Article
Magnetic Resonance-Guided Focused Ultrasound Surgery for Gynecologic Indications.

Magnetic resonance-guided focused ultrasound surgery (MRgFUS) appears to be an effective and safe treatment for uterine fibroids and adenomyosis, particularly in women who wish to preserve fertility. In abdominal wall …

Published: March 27, 2024, midnight
Read Full Article
Focused ultrasound surgery Gynecologic indications MRI MRgFUS
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!